Beta-1,3-glucan synthase complex (GS)

The **beta-1,3-glucan synthase complex** is a multi-subunit enzyme complex primarily found in fungi, essential for synthesizing linear (1,3)-β-D-glucan—a key structural polysaccharide of the fungal cell wall[2][3][4]. The core catalytic subunit is **FKS1**, regulated by the small GTPase **Rho1**; additional FKS isoforms (FKS2, FKS3) contribute to activity under stress or specific growth conditions[2][4]. This complex catalyzes the polymerization of UDP-glucose into β-1,3-glucan chains, which are then extruded into and organized within the cell wall[6]. β-1,3-glucan synthase is highly conserved among fungal species but absent in humans, making it a validated target for antifungal therapy[2][4]. Inhibition of this enzyme complex by echinocandins and other drugs disrupts cell wall synthesis, causing selective fungal death. Mutations in FKS1/FKS2 can confer resistance to these drugs[4]. The product, β-1,3-glucan, can be detected in patient serum and serves as a surrogate marker for invasive fungal infection. Structurally, the enzyme is a large, membrane-integrated glycosyltransferase with multiple transmembrane domains and key cytoplasmic catalytic sites[3][6]. The regulatory role of Rho1 and the oligomeric state of the complex are essential for activity. The enzyme plays a central role in fungal pathogenicity, cell integrity, and morphogenesis[2][4]. Drug targeting of β-1,3-glucan synthase is considered safe in humans due to its fungal specificity, but resistance and rare allergic-type reactions are recognized concerns[4].

Other names

β-D-glucan synthase(1,3)-β-D-glucan synthaseBeta-1,3-glucan synthaseFKS1 complexFKS1-Rho1 complexGS complex

Inhibition of β-1,3-glucan synthesis, leading to cell wall weakening and fungal cell lysis. Blockage of enzymatic activity of FKS1 and associated subunits. Non-competitive and competitive inhibition mechanisms reported for different drug classes.